Abstract:Phase I clinical trials represent the first step in bringing promising new treatments from the laboratory to the clinic. Although the importance of phase I clinical trials is widely recognized, there is currently no consensus among the scientific, medical, and statistical communities on how best to do these studies in humans. With the advent of targeted therapies, it has become evident that we need to tailor the design of phase I studies for the particular drug class under investigation and any endpoints that are being defined. The National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC) provides broad external scientific and clinical input on the design and prioritization of early-phase clinical trials with agents for which the NCI Cancer Therapy Evaluation Program (CTEP) holds an Investigational New Drug (IND) application through the U.S. Food and Drug Administration (FDA). The IDSC has formed a number of task forces and working groups, including the Clinical Trial Design Task Force and the Biomarker Working Group, many with membership from within the IDSC as well as external experts, including participants from academia, the pharmaceutical industry, and regulatory authorities. The Clinical Trials Design Taskforce sponsored a Phase I Workshop with the primary goal being to develop consensus recommendations for the optimal design of phase I studies. The primary focus included (1) efficient trial designs, (2) phase I drug combinations, and (3) appropriate statistical and correlative endpoints. In this CCR Focus series, articles summarize key aspects and recommendations on phase I studies (including combination trials), such as design, use of biomarkers, the European Union and Japanese perspectives on design, requirements for first-in-human and other phase I studies, and ensuring regulatory and International Conference on Harmonization (ICH) compliance. A final article summarizes recommendations for the design and conduct of phase II studies.

Discussions on the standardized safety evaluation of new drugs in phase I clinical trials

Study on the key steps for the subject medication of phase Ⅰ clinical trials

Current trends of nonclinical safety evaluation for new drugs

Study on the Standardization of Initial Ethical Review of Drug Clinical Trial

An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics

[Report standards for clinical comprehensive evaluation of Chinese patent medicine]

Bridging Studies in Clinical Trials for New Drug Application

[Safety Assessment in Radomized Controlled Clinical Trials].

Safety assessment of psychotropic drugs in clinical trial

Innovation drug approvals based on a bridging study: from concept to practice

Problems and Countermeasures for the Ethical Review on the Drug Clinical Trials in China

Statistical Considerations on Drug Safety in Clinical Trials

2000-2023 over two decades of ICH S7A: has the time come for a revamp?

Discussion on management of new drug clinical trials proj'ect

Introduction of Association The British Pharmaceutical Industry ’ s guidelines for phase 1 clinical trials of 2012

Expert Consensus on Key Issues of Quality Control in Clinical Trials of New Drugs of Traditional Chinese Medicine

The Discussion on strategy improving the safety in human bioequivalence study

Strategic Shift of Statistical Review on Data Quality Assessment for New Drug Applications in China.

Technical specifications for hospital-based intensive monitoring of post-marketing Chinese patent medicine

Exploration of the Method of Developing Core Data Sets for Post-marketing Clinical Safety Evaluation of Chinese Proprietary Medicine

Discussion on problems in conducting the clinical trials on off-label use of drug